NEW HOPE, Pa.–(BUSINESS WIRE)–VerdePharmHealth right this moment introduced the signing of an unique nationwide group buying settlement with Altopa, creator of the Oblend™, a patented machine and expertise platform that is ready to create personalised, constant merchandise that leverage the brand new science round customized blended terpenes which are important to maximizing affected person outcomes.
With the Oblend platform, VerdePharm and Altopa are aimed toward creating unprecedented entry to plant medication by offering entry to confirmed formulations that embrace terpenes that concentrate on particular medical circumstances and collect suggestions on affected person outcomes. “There are a host of botanical extracts, including cannabinoids and terpenes, that work in concert to modulate how cannabis addresses targeted symptoms, a phenomenon known as ‘the entourage effect.’ This safe, precise and consistent alternative to many common over-the-counter and prescription medications has a valuable role to play in addressing individual patient symptoms and conditions,” mentioned Dr. Ralph Boccia, Medical Chair for VerdePharmHealth. “Altopa’s product line is expert-formulated to target specific health benefits and provides a unique capability to tailor to an individual’s specific needs.”
“VerdePharmHealth and Altopa’s missions are strongly aligned. Both companies are working to provide accessibility, enhance outcomes, collect clinical evidence, standardize protocols, and move cannabis science forward. The Oblend platform is the first device brought to market that gives access to a range of personalized pharma-grade cannabinoid based wellness products and the ability to create personalized solutions. We are delighted that VerdePharmHealth’s members now have access to the Oblend platform,” says Nicole Wicker, Altopa’s CEO. “This partnership will provide preferred access and pricing to VerdePharm’s established and growing channel of progressive healthcare providers.”
“We’re excited to add Oblend’s unique-to-industry capability to VerdePharmHealth’s full care-cycle offering including provider reference, decision-support & patient engagement tools”, mentioned Jesse Hollingsworth, founder & Chief Executive Officer, VerdePharmHealth. “Altopa is a strong match for VerdePharmHealth with its unique capabilities around the formulation and production of medical cannabis solutions for the healthcare market. This is fully aligned with our approach to partnering with innovative and highly compliant manufacturers on behalf of our network and their patients.” The firms plan future collaborations targeted on observational real-world proof research round plant based mostly options to opioids and different prescribed drugs and their usually devastating unwanted side effects.
VerdePharmHealth, the primary group of its variety within the U.S., supplies complete multi-specialty group buying, medical options, and healthcare expertise designed to drive high-level dedication and affordability for members via accessibility of high quality hashish merchandise from prequalified producers and leveraging of medical providers and strong expertise to enhance choices for interventions on the level of care and seize real-world proof. Utilizing retrospective information and medical research for decision-support and standardization of appropriate-use within the care supply course of is a central pillar in the direction of reaching outcomes. For extra info, go to www.verdepharmhealth.com or comply with VerdePharmHealth on LinkedIn.
Altopa, a Seattle based mostly expertise firm, has a said mission to empower wellness via a proprietary mix of nature, science and expertise. The Oblend Platform solves vital business challenges and boundaries to the mainstream shopper adoption of medicinal hashish associated to an absence of predictability, consistency and most significantly, shopper confidence. Oblend has been designed to assist the supplier, affected person relationship and to ship an unprecedented stage of confidence – confidence that with our platform, customers can entry the best formulations for their physique’s distinctive wants, get the product consistency they count on and expertise predictable advantages and results. For extra info, go to http://www.oblend.com
Matters mentioned on this launch that aren’t statements of historic or present details, resembling anticipated financial savings and different anticipated advantages to members and suppliers, as mentioned herein, are “forward-looking statements” which can contain recognized and unknown dangers, uncertainties and different components which will trigger the precise outcomes, efficiency or achievements of VerdePharmHealth and its subsidiaries to be materially totally different from historic outcomes or from any future outcomes or projections expressed or implied by such forward-looking statements. Accordingly, readers mustn’t place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such dangers and uncertainties, readers are urged to contemplate statements within the conditional or future tenses or that embrace phrases resembling “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be unsure and forward-looking. Forward-looking statements might embrace feedback as to VerdePharm’s beliefs and expectations as to future occasions and tendencies affecting its enterprise and are essentially topic to uncertainties, a lot of that are outdoors VerdePharm’s management. Forward-looking statements communicate solely as of the date they’re made. VerdePharm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case that happen after that date.